Powles T J, Gordon C, Coombes R C
Cancer Res. 1982 Aug;42(8 Suppl):3458s-3460s.
Multiple-endocrine therapy with combinations of various types of treatment has not been evaluated properly in spite of the success of individual types of hormone treatment. This paper reports the early results of a randomized controlled clinical trial comparing tamoxifen (10 mg 2 times/day)-amino-glutethimide (250 mg 3 times/day)-danazol (100 mg 3 times/day)-hydrocortisone (20 mg 2 times/day) (TAD) with tamoxifen (10 mg 2 times/day). Analysis of the first 107 assessable patients indicates objective response (criteria of the International Union Against Cancer) in 33% of patients receiving tamoxifen versus 50% of patients receiving TAD. Duration of response to TAD is identical to duration of response to tamoxifen alone. TAD is well tolerated, and toxicity, although greater than or tamoxifen, is acceptable.
尽管单一类型的激素治疗取得了成功，但多种类型治疗联合的多内分泌治疗尚未得到恰当评估。本文报告了一项随机对照临床试验的早期结果，该试验比较了他莫昔芬（10毫克，每日2次）-氨鲁米特（250毫克，每日3次）-达那唑（100毫克，每日3次）-氢化可的松（20毫克，每日2次）（TAD）与他莫昔芬（10毫克，每日2次）。对前107例可评估患者的分析表明，接受他莫昔芬治疗的患者中有33%出现客观缓解（国际抗癌联盟标准），而接受TAD治疗的患者中有50%出现客观缓解。TAD的缓解持续时间与单独使用他莫昔芬的缓解持续时间相同。TAD耐受性良好，毒性虽比他莫昔芬大，但仍可接受。
